Artelo Biosciences Faces Nasdaq Compliance Challenge

Artelo Biosciences ( (ARTL) ) has issued an update.

On May 22, 2025, Artelo Biosciences received a notice from Nasdaq indicating non-compliance with the minimum stockholders’ equity requirement of $2,500,000, as the company reported only $652,000 in its quarterly report ending March 31, 2025. Although this notice does not immediately affect the company’s Nasdaq listing, Artelo has until July 7, 2025, to submit a compliance plan and potentially until November 18, 2025, to meet the requirements. The company is exploring options to address the deficiency but faces uncertainty regarding the acceptance of its compliance plan and the potential success of any appeals against delisting.

The most recent analyst rating on (ARTL) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.

Spark’s Take on ARTL Stock

According to Spark, TipRanks’ AI Analyst, ARTL is a Underperform.

Artelo Biosciences faces substantial financial hurdles with no revenue and continuous losses, heavily impacting its overall score. Technical indicators do not show a strong recovery trend, and the lack of new guidance from earnings calls further adds uncertainty. Valuation metrics are unfavorable due to negative earnings, making the stock less appealing to investors.

To see Spark’s full report on ARTL stock, click here.

More about Artelo Biosciences

Artelo Biosciences, Inc. operates in the biotechnology industry, focusing on the development of therapeutics that target lipid signaling pathways.

Average Trading Volume: 401,942

Technical Sentiment Signal: Sell

Current Market Cap: $3.13M

For a thorough assessment of ARTL stock, go to TipRanks’ Stock Analysis page.